register

News & Trends - MedTech & Diagnostics

Zimmer Biomet and Device Technologies announce partnership in orthopaedics

Health Industry Hub | April 12, 2021 |

MedTech News: Zimmer Biomet and Device Technologies, both major powerhouses in musculoskeletal healthcare, today announced a partnership to improve orthopaedic patient outcomes across Australia and New Zealand.

Zimmer Biomet has appointed Device Technologies as an exclusive distributor in Australia and New Zealand for its Sports Medicine and Surgical product portfolios from 12 April 2021, with Foot & Ankle and Trauma product portfolios to follow on 31 May 2021.

“The partnership with Device Technologies underscores a new business model that focuses on Zimmer Biomet’s core strengths while leveraging Device Technologies’ distribution and support network for greater growth in the target product portfolios in Australia and New Zealand,” said Warren Ballinger, Zimmer Biomet’s ANZ President. “The Device Technologies network will provide Zimmer Biomet with greater market penetration across Sports Medicine, Surgical, Foot & Ankle and Trauma. It will allow us to focus more on our hip, knee, shoulder, elbow, CMFT, Spine and Early Intervention product ranges as well as our suite of technology-based solutions,” he added.

“Partnering with Zimmer Biomet is an exciting step forward for Device Technologies. We are confident in the shared values between the two companies and that Zimmer Biomet’s product offering will complement our orthopaedic product portfolio and service Device Technologies customers well,” said Mick Trevaskis, Device Technologies CEO. “It’s a partnership that will see both companies proceed well together into the future.”

With over 90 years in the industry, Zimmer Biomet continues to be a driving force in musculoskeletal healthcare. Its unwavering focus on the needs of patients and surgeons drives the innovative and technologically advanced product solutions they offer. By combining with the extensive orthopaedic partnership network and loyal customer base of Device Technologies, Zimmer Biomet intends to further consolidate and strengthen its presence and reputation in Australia and New Zealand.

With 28 years’ experience in the orthopaedic market in Australia and New Zealand, Device Technologies boasts a history of consistent sales success; in 2019 the Device Technologies orthopaedic business had over 55% market share in Sports Medicine in Australia.

Zimmer Biomet’s product offerings will complement Device Technologies’ holistic portfolio, encompassing advanced orthopaedic products and technologies, product education, dedicated technical service and thorough clinical support. At present, 85% of orthopaedic surgeons in Australia and New Zealand are Device Technologies customers and 80% of current orthopaedic registrars across the two countries have participated in educational courses through Device Technologies.


News & Trends - MedTech & Diagnostics

APAC medtech company scores TGA approval in heart disease

APAC medtech company scores TGA approval in heart disease

Health Industry Hub | October 4, 2024 |

MedTech & Diagnostics News: An Asia Pacific medtech company has announced that its flagship drug-eluting stent (DES) has received regulatory […]

More


News & Trends - MedTech & Diagnostics

New state-based pilot to back home-grown medtech innovation

New state-based pilot to back home-grown medtech innovation

Health Industry Hub | October 4, 2024 |

MedTech & Diagnostics: In a bid to enhance opportunities for local medtech manufacturers to sell to health services, a connected […]

More


News & Trends - Pharmaceuticals

Ferring unveils first real-world evidence for faecal calprotectin approach in ulcerative colitis

Ferring unveils first real-world evidence for faecal calprotectin approach in ulcerative colitis

Health Industry Hub | October 4, 2024 |

Pharma News: Ferring Pharmaceuticals has announced results from a new study, which provides the first real-world evidence supporting the efficacy […]

More


News & Trends - Pharmaceuticals

Bayer partners with RACGP, calls for MBS reforms to boost access to long-acting contraceptives

Bayer partners with RACGP, calls for MBS reforms to boost access to long-acting contraceptives

Health Industry Hub | October 4, 2024 |

Pharma News: Australian women are calling for more accurate information about their contraceptive options, with 70% feeling inadequately educated about […]

More


This content is copyright protected. Please subscribe to gain access.